LFS and OS are unaffected by CRS treatment strategy or administered CRS-directed treatment. All subjects were analyzed for LFS and OS following CAR T-cell infusions. The DLT cohort (red) and the EI cohort (blue) had similar LFS Kaplan-Meier curves (A) and OS Kaplan-Meier curves (B). Separately, all subjects were categorized per the specific intervention received. Intervention groups are steroid with or without tocilizumab (green), tocilizumab (blue), and none (red), with no difference between LFS Kaplan-Meier curves (C) and OS Kaplan-Meier curves (D).